## Diane Nugent Or Diane J Nugent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2926152/publications.pdf

Version: 2024-02-01

58 papers 3,605 citations

361296 20 h-index 51 g-index

60 all docs

60 docs citations

60 times ranked

2978 citing authors

#	Article	IF	CITATIONS
1	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	13.9	1,681
2	PFA-100â,,¢ System: A New Method for Assessment of Platelet Dysfunction. Seminars in Thrombosis and Hemostasis, 1998, 24, 195-202.	1.5	415
3	Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. British Journal of Haematology, 2009, 146, 585-596.	1.2	230
4	Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood, 2012, 119, 5111-5117.	0.6	116
5	Wiskott& ndash; Aldrich syndrome: diagnosis, current management, and emerging treatments. The Application of Clinical Genetics, 2014, 7, 55.	1.4	112
6	Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Preference and Adherence, 2015, 9, 1549.	0.8	91
7	Identification of Patients with RAG Mutations Previously Diagnosed with Common Variable Immunodeficiency Disorders. Journal of Clinical Immunology, 2015, 35, 119-124.	2.0	70
8	Expanding the Mutation Spectrum Affecting $\hat{l}$ ±IIb $\hat{l}$ 23 Integrin in Glanzmann Thrombasthenia: Screening of the <i>ITGA2B &lt;  i&gt; and <i> ITGB3 &lt;  i &gt; Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.</i></i>	1.1	67
9	The Effect of Antiplatelet Autoantibodies on Megakaryocytopoiesis. International Journal of Hematology, 2005, 81, 94-99.	0.7	61
10	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	2.5	57
11	Evidence for the benefits of prophylaxis in the management of hemophilia A. Thrombosis and Haemostasis, 2006, 96, 433-440.	1.8	56
12	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	1.0	54
13	Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children. Journal of Pediatrics, 2014, 165, 600-605.e4.	0.9	49
14	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	0.5	46
15	Corifactâ,,¢/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thrombosis Research, 2012, 130, S12-S14.	0.8	40
16	The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12690.	1.0	37
17	Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review. Journal of Blood Medicine, 2018, Volume 9, 185-192.	0.7	35
18	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	0.6	34

#	Article	IF	CITATIONS
19	Monozygotic Twin Pair Showing Discordant Phenotype for X-linked Thrombocytopenia and Wiskott–Aldrich Syndrome: a Role for Epigenetics?. Journal of Clinical Immunology, 2011, 31, 773-777.	2.0	30
20	Evidence of a disability paradox in patientâ€reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	1.0	25
21	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	1.8	22
22	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	0.7	21
23	Isolation and characterization of the $\hat{l}\pm$ and $\hat{l}^2$ chains of human platelet glycoprotein Ib. Biochemical and Biophysical Research Communications, 1987, 147, 526-534.	1.0	20
24	Value of prophylaxis vs onâ€demand treatment: Application of a value framework in hemophilia. Haemophilia, 2018, 24, 755-765.	1.0	20
25	Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency. Journal of Clinical Immunology, 2016, 36, 725-732.	2.0	19
26	Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload. Pediatric Transplantation, 2012, 16, E69-73.	0.5	18
27	Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia. Seminars in Hematology, 2016, 53, S70-S72.	1.8	16
28	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. Seminars in Thrombosis and Hemostasis, 2017, 43, 059-068.	1.5	15
29	Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia, 2021, 27, 769-782.	1.0	15
30	High-grade heart block requiring transvenous pacing associated with multisystem inflammatory syndrome in children during the COVID-19 pandemic. HeartRhythm Case Reports, 2020, 6, 811-814.	0.2	14
31	Hemorrhage Involving the Upper Airway in Hemophilia. Clinical Pediatrics, 1986, 25, 436-439.	0.4	12
32	Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances, 2021, 5, 1617-1626.	2.5	11
33	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. International Journal of Infectious Diseases, 2021, 113, 1-6.	1.5	11
34	Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875.	1.0	8
35	Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia. Pediatric Transplantation, 2013, 17, E104-7.	0.5	7
36	Comparison of Three Different Platelet Function Assays to Determine Aspirin Sensitivity Blood, 2004, 104, 3901-3901.	0.6	7

#	Article	lF	Citations
37	Successful cord blood transplantation in a patient with malignant infantile osteopetrosis and hemophilia. Pediatric Transplantation, 2013, 17, E20-4.	0.5	6
38	Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 1055-1063.	2.0	6
39	Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes. Journal of Pediatric Hematology/Oncology, 2018, 40, e319-e322.	0.3	6
40	Molecular Specificity of Anti-IIb/IIIa Human Antibodies. Seminars in Thrombosis and Hemostasis, 1995, 21, 60-67.	1.5	5
41	X-linked Hyper IgM Syndrome. Journal of Pediatric Hematology/Oncology, 2012, 34, e212-e214.	0.3	5
42	Platelet genomics: the role of platelet size and number in health and disease. Platelets, 2017, 28, 27-33.	1.1	5
43	Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients. Pediatric Infectious Disease Journal, 2021, 40, 606-611.	1.1	5
44	Rare factor deficiencies. Current Opinion in Hematology, 2012, 19, 380-384.	1.2	4
45	Promising biomarkers for the prediction of catheterâ€related venous thromboembolism in hospitalized children: An exploratory study. Pediatric Blood and Cancer, 2019, 66, e27870.	0.8	4
46	Sensitivity and Efficacy in Measurement of Anti-Platelet Medications Blood, 2005, 106, 1253-1253.	0.6	4
47	Successful treatment of secondary graft failure following unrelated cord blood transplant with hematopoietic growth factors in a pediatric patient with <scp>F</scp> anconi anemia. Pediatric Transplantation, 2015, 19, E181-4.	0.5	3
48	Hemophilia – Impact of Recent Advances on Management. Indian Journal of Pediatrics, 2020, 87, 134-140.	0.3	3
49	Safety and effectiveness of recombinant factor XIIIâ€A2 in congenital factor XIII deficiency: Realâ€world evidence. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12628.	1.0	3
50	Safe and Effective Use Of Romiplostim and Eltrombopag In Children With ITP. Blood, 2013, 122, 3541-3541.	0.6	2
51	OP16 A Patient-centered Value Framework For Healthcare In Hemophilia. International Journal of Technology Assessment in Health Care, 2017, 33, 8-9.	0.2	1
52	A Patient With Familial Bone Marrow Failure and an Inversion of Chromosome 8. Journal of Pediatric Hematology/Oncology, 2011, 33, 626-627.	0.3	0
53	Inflammatory polyps following successful HLAâ€matched cord blood transplantation in a patient with Xâ€linked lymphoproliferative syndrome. Pediatric Transplantation, 2012, 16, E188-91.	0.5	O
54	PP111 Toward Healthy Coagulation In Hemophilia. International Journal of Technology Assessment in Health Care, 2018, 34, 108-108.	0.2	0

#	Article	IF	CITATIONS
55	#12: The Safety and antibody kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S7-S7.	0.6	O
56	Cytokine Response and Genotype Frequencies in ITP of Childhood Blood, 2007, 110, 569-569.	0.6	0
57	Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency. Blood, 2013, 122, 3613-3613.	0.6	O
58	Psychosocial outcomes of siblings of pediatric stem cell transplant survivors Journal of Clinical Oncology, 2014, 32, 9528-9528.	0.8	0